COLLISION TUMOR: COEXISTENCE OF TWO DIFFERENT MALIGNANCIES IN SAME THYROID LOBE

AUTHORS:
B. Vieira (Vila Real, Portugal) , C. Santos (Vila Real, Portugal) , J. Carvas (Vila Real, Portugal) , A. Ribeiro (Vila Real, Portugal) , G. Guidi (Vila Real, Portugal) , M. Dupont (Vila Real, Portugal) , J. Pinto-de-Sousa (Vila Real, Portugal)
Background:
Papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma (FTC) are common differentiated thyroid cancers, but the detection of a collision tumor is an extremely rare event.
Methods:
Literature review and a case report of concurrent PTC and FTC in one thyroid lobe, featuring comprehensive radiological and histological images.
Results:
A 49-year-old female presented with an anterior neck swelling of 9-month duration with no other associated symptoms. On examination, she was found to have a palpable nodule of the right lobe of thyroid. Her thyroid function tests were normal. Neck ultrasound revealed a homogenous thyroid interrupted by two nodules in the right lobe: one in the lower third (11 mm x 12 mm x 13 mm), and the other in the posterior middle third with macrocalcifications (7 mm x 6 mm x 7 mm). Fine-needle aspiration cytology of the smaller nodule reported a papillary neoplasm. Right hemithyroidectomy was performed without complications. Microscopic examination showed a 7 mm classic papillary microcarcinoma with extracapsular extension and suspected vascular invasion. The largest macroscopically identified lesion was a 16 mm minimally invasive follicular carcinoma with focal capsular invasion. As a result, a completion thyroidectomy was performed without complications. Histopathology showed a 2 mm nodule, a classic papillary microcarcinoma without capsular, vascular, or perineural invasion, and not intersecting the surgical margin. She is currently asymptomatic with normal thyroid function tests and thyroglobulin levels.
Conclusions:
Rare and globally reported, collision tumors present diagnostic and therapeutic challenges due to dual pathology. Limited literature hinders specific treatment guidelines, necessitating tailored management based on each carcinoma's extent.